Heat shock proteins induce T cell regulation of chronic inflammation

F Hauet-Broere, L Wieten, T Guichelaar, S Berlo, R van der Zee, W Van Eden

The significance of immune responses to certain heat shock proteins (HSPs) that develop in virtually all inflammatory diseases is only now becoming clear. In experimental models, HSPs prevent or arrest inflammatory damage, and initial clinical trials in chronic inflammatory disease have shown HSP peptides to promote production of anti-inflammatory cytokines—indicating immunoregulatory potential. HSPs are ubiquitous self-antigens that are highly expressed in inflamed tissues. The prokaryotic homologous proteins, present in every bacterial species, are dominantly immunogenic. This is striking, especially as these proteins have large areas of sequence homologies with the host (mammalian) counterparts. In several experimental models of autoimmune diseases, immunisation with bacterial HSPs inhibited disease development, as did oral/nasal administration. Based on the experimental evidence so far, it is tempting to speculate that: firstly, exposure to homologues of these self-antigens, as present in, for instance, the bacterial intestinal flora, has a decisive impact on the regulation of self-tolerance at the level of T cells; and secondly, such proteins or their derivative peptides may have a role in an antigen specific immunother-apy approach involving modulation of relevant T cells, without the immediate necessity of defining disease specific autoantigens. Recent findings in experimental asthma and atherosclerosis have indicated that the field of application of such immunotherapy can be broader than just autoimmunity.

Heat shock proteins (HSPs) were originally discovered as proteins induced by heat stress and were named accordingly. Nevertheless, other stressful stimuli, such as hypoxia, toxic chemicals, and inflammation, also induce HSP expression. Several distinct families of HSPs can be distinguished, based on their molecular weight: HSP10, HSP40, HSP60, HSP70, HSP90, and HSP100. All the members of the HSP families play an important role in cell survival under both physiological and stress conditions due to their function in chaperoning other intracellular proteins during (re)folding and assembly.

HSPs are evolutionary highly conserved proteins and are abundantly expressed in both prokaryotic and eukaryotic organisms. Despite their evolutionary sequence conservation, even between microbes and their host self-homologues, the microbial proteins are highly immunogenic and have been implicated in the control of autoimmune inflammation due to a cross-reactive immune response. HSP immunisations have been shown to inhibit autoimmune disorders such as diabetes and arthritis both in animal models and in initial clinical trials in patients with chronic inflammatory disease.

Over the past years, several research groups have shown that HSP reactive T cells might play a role in this regulatory function and in the induction of anti-inflammatory cytokines in chronic inflammation.

IMMUNE SUPPRESSION
The observation that eukaryotic and prokaryotic HSPs have high sequence homology prompted the hypothesis that HSPs might be potential candidates for molecular mimicry and could act as potentially dangerous autoantigens. Studies showing that elevated HSP levels and anti-HSP antibodies are present in autoimmune inflammatory responses, such as arthritis, multiple sclerosis, and diabetes, seemed to support this hypothesis. Intriguingly though, initial studies in adjuvant arthritis, a Mycobacterium tuberculosis induced arthritis, demonstrated that immunisation with the dominant mycobacterial antigen, HSP60, abrogated subsequently induced disease.

This protective effect is not exclusive for adjuvant arthritis and has been detected in an array of chronic inflammatory animal models, such as experimental autoimmune encephalomyelitis, collagen induced arthritis, and diabetes. As the latter models do not depend on immunisation with M. tuberculosis, the suppressive effect of mycobacterial HSP60 seems independent of the subsequent disease inducing antigen. In addition, experiments exploring the suppressive capacity of mycobacterial HSP60 in more detail have illustrated that only the self-HSP cross-reactive peptides induced protection against adjuvant arthritis via the induction of self-HSP-reactive regulatory T cells.

INNATE IMMUNITY
Besides modulating inflammatory responses via the induction of HSP-reactive regulatory T cells, HSPs can directly activate the immune system through surface receptors such as toll-like receptor (TLR)2, TLR4, CD91, CD40 and CD14. However, such reports have been questioned by studies indicating that proinflammatory activity of HSP via such receptors was solely due to bacterial contaminants. Even though this cannot be entirely excluded, because regular tests to exclude that contamination by lipopolysaccharide (LPS) is responsible for the observed effects (such as polymyxin B preincubation and/or protein denaturing by boiling HSP), might not affect all other bacterial compounds, several reports show that highly purified HSP can still activate dendritic cells and macrophages. For example, HSP derived from murine liver and kidney has been shown to be able to activate dendritic cells and macrophages.

In addition to these reports of highly purified HSP, other papers have described distinct activation of TLR signalling after HSP binding. HSP induced signalling via TLR is

Abbreviations: HSP, heat shock protein; IL, interleukin; PG, proteoglycan; PGIA, proteoglycan induced arthritis; TLR, toll-like receptor
dependent on CD14 expression, whereas LPS signalling is still 
edefined in the absence of the coreceptor, though signalling is 
enhanced in the presence of CD14. Furthermore HSP70 
duces a Ca²⁺ influx in monocytes after TLR binding, which is 
absent after LPS triggering.25 26 Moreover, HSP60 induced 
TLR signalling has been shown to be dependent on 
endocytosis, in contrast with LPS, which signals at the cell 
surface.27

Although extensive data support a role for HSP in the 
avtivation of both innate and adaptive immune cells (fig 1), it 
is apparent from the above mentioned data that knowledge of 
the origin and purity of the HSP proteins used in 
experiments is important.

**MECHANISMS**

Initial reports showed that immunisation with mycobacterial 
HSP60 protected animals against adjuvant arthritis. 
Characterisation of the protective mycobacterial HSP60 
epitopes showed that only conserved epitopes that induced a 
T cell response to self-HSP60 abrogated arthritis induc-
tion. T cell lines specific for this self-HSP peptide could 
transfer protection against the induction of adjuvant arthritis 
in Lewis rats.

Since upregulation of HSPs is part of an inflammatory 
response, self-HSP-reactive T cells with a regulatory phenoe-
type might be part of the physiological termination of the 
immune response. Several studies in which bacterial 
HSP60 or HSP70 pre-immunisations were used to protect 
against subsequently induced inflammatory diseases have 
shown induction of interleukin (IL)-10 producing T cells on 
restimulation with both bacterial and self-HSPs.1 17 28 29 Also 
in a murine model of proteoglycan induced arthritis (PGIA), 
mycobacterial HSP70 protected against disease induction. 
Analysis of the lymphoid cells obtained from the HSP70 
protected mice revealed the presence of IL-10 producing cells 
on restimulation with HSP70 as well as with the arthritis 
inducing PG. In other words, HSP immunisation has led to 
the production of a regulatory phenotype in both HSP specific 
cells and cells specific for the disease associated PG antigen. 
This indicates that HSP immunisation might spread regulatory 
activity in cases where the autoantigen is unknown to 
potentially proinflammatory T cells and still can induce 
antigen specific regulation (Berlo et al, unpublished results, 2006). Recently we have developed a new TCR-Tg mouse that 
expresses T cells specific for arthritis inducing human 
cartilage PG.30

To explore the mechanism of immune regulation by 
antigen specific IL-10 producing T cell in an arthritis model in 
more detail, we have retrovirally transduced these PG 
specific cells with the murine IL-10 gene and green 
fluorescent protein (GFP) as selection marker. Transfer of 
these antigen specific IL-10+ cells not only suppressed the 
induction of arthritis in acceptor mice compared with cells 
transduced with GFP alone, but also induced IL-10 producing 
proteoglycan specific T cells within these mice, thereby 
spreading their regulatory function. Moreover, transfer of T 
cells with irrelevant TCR specificity did not abolish the 
development of PGIA when transduced with the same 
construct, emphasising the importance of antigen specificity 
of the regulatory T cells (Guichelaar et al, unpublished results, 2006). These data suggest that spreading of the regulatory 
capacity is both dependent on IL-10 production and TCR 
specificity. However, it is attractive to assume that compar-
able mechanisms play a role in the spreading of tolerance 
after HSP70 immunisation in PGA.

Self-HSP-reactive T cells are not only part of the adult T cell 
repertoire, but also are considered to play an important role in 
maintaining immune homeostasis. Studies using trans-
genic animals overexpressing HSP60 still displayed self-HSP-
reactive T cell responses, underlining that the lack of central 
deletion is not because of the absence of HSP expression in 
the thymus.31 This suggests that during T cell development in 
the thymus central deletion is either not occurring or not 
complete, allowing the development of self-HSP-reactive T 
cells. Under homeostatic conditions, these self-reactive T 
cells do not induce autoimmune inflammatory responses. 
Therefore, these self-HSP-specific T cells must be kept in a 
tolerant or regulatory mode. This can be achieved by the 
regular exposure to regulatory cytokines such as IL-10. IL-10 
is known to be associated with stress (stressed cells do 
produce IL-10) and therefore exposure to HSP. Expansion of 
HSP-reactive T cells usually occurs in the presence of IL-10. 
In addition, HSP expression is upregulated in all cells at the 
site of inflammation, which includes non-professional anti-
gen presenting cells lacking costimulatory molecules. These 
cells will induce an anergic state in these HSP specific T cells. 
Finally, high levels of commensal HSPs are present at the 
normal mucosa, and since mucosal antigen exposure induces regulatory T cells32–34 exposure to such HSPs might favour the 
induction of HSP specific mucosal regulatory T cells. This is 
supported by studies showing that mucosal administration of 
HSP60 indeed induces regulatory T cells that mirror the 
phenotype of mucosally induced regulatory T cells to 
previously novel antigens in IL-10 production.35 Furthermore, changes in the gut microflora have been shown to 
change the susceptibility to subsequently induced arthri-
tis.36–39

Recent reports in the literature further support the role of 
HSP induced regulatory activity. Besides direct induction of 
HSP-specific regulatory T cells due to presentation at 
tolerance inducing mucosal sites, one can speculate that 
HSP might aid in the expansion of existing regulatory T cells 
via antigen non-specific responses.

As described above HSPs have the ability to directly 
interact with different cells of the immune system by
triggers TLR. HSP60 induced TLR signalling on T cells, independent of LPS, enhanced GATA3 expression, suggesting the induction of a T helper 2 phenotype. 47 Also, HSP70 has been shown to induce anti-inflammatory cytokines in both peripheral blood and synovial derived monocytes from patients with arthritis. In addition, HSP70 has been shown to enhance IL-10 production by mouse bone marrow dendritic cells.48 These data suggest that HSPs might induce a microenvironment that is favourable for the induction of regulation.

In addition to direct signalling of HSP via TLR on antigen presenting cells, HSP60 has been shown to specifically activate T cells via TLR2 and regulate migration and adhesion.49 Intriguingly, TLR2 signalling on regulatory T cells has been shown to expand existing CD25+ regulatory T cells. 50 In line with these findings, recently a fascinating study showed that HSP60 specific T cells from patients had a regulatory phenotype, producing IL-10 and transforming growth factor β. 51 Moreover, among patients with rheumatoid arthritis, those with HSP60-reactive synovial T cells acquired the regulatory phenotype on in vitro restimulation with self-HSP60 and suppressed production of tumour necrosis factor beta by autologous blood T cells.42 Initial clinical trials using HSP-derived peptides have shown promising results in dampening the clinical disease score in ongoing disease.9 10

In conclusion, it is clear that HSP proteins and peptides have an immunomodulatory role. Immune modulation is essential for an organism for prevention of excessive inflammation and subsequent organ damage, but inflammatory reactions are a prerequisite to eradicate harmful pathogens. Therefore, the immune system has developed several tightly regulated mechanisms, which, depending on time, location, and intensity of the inflammatory response, will be able to regulate the immune response. HSPs might play an important role in such an educated regulatory mechanism and might provide a strategic target for developing therapies in various inflammatory disorders, including rheumatoid arthritis.

**References**

7. Fink AL, Albani S, Birk OS, Wendling U. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4. In line with these findings, recently a fascinating study showed that HSP60 specific T cells from patients had a regulatory phenotype, producing IL-10 and transforming growth factor β. Moreover, among patients with rheumatoid arthritis, those with HSP60-reactive synovial T cells acquired the regulatory phenotype on in vitro restimulation with self-HSP60 and suppressed production of tumour necrosis factor beta by autologous blood T cells.42 Initial clinical trials using HSP-derived peptides have shown promising results in dampening the clinical disease score in ongoing disease.9 10

In conclusion, it is clear that HSP proteins and peptides have an immunomodulatory role. Immune modulation is essential for an organism for prevention of excessive inflammation and subsequent organ damage, but inflammatory reactions are a prerequisite to eradicate harmful pathogens. Therefore, the immune system has developed several tightly regulated mechanisms, which, depending on time, location, and intensity of the inflammatory response, will be able to regulate the immune response. HSPs might play an important role in such an educated regulatory mechanism and might provide a strategic target for developing therapies in various inflammatory disorders, including rheumatoid arthritis.

**References**

7. Fink AL, Albani S, Birk OS, Wendling U. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4. In line with these findings, recently a fascinating study showed that HSP60 specific T cells from patients had a regulatory phenotype, producing IL-10 and transforming growth factor β. Moreover, among patients with rheumatoid arthritis, those with HSP60-reactive synovial T cells acquired the regulatory phenotype on in vitro restimulation with self-HSP60 and suppressed production of tumour necrosis factor beta by autologous blood T cells.42 Initial clinical trials using HSP-derived peptides have shown promising results in dampening the clinical disease score in ongoing disease.9 10

In conclusion, it is clear that HSP proteins and peptides have an immunomodulatory role. Immune modulation is essential for an organism for prevention of excessive inflammation and subsequent organ damage, but inflammatory reactions are a prerequisite to eradicate harmful pathogens. Therefore, the immune system has developed several tightly regulated mechanisms, which, depending on time, location, and intensity of the inflammatory response, will be able to regulate the immune response. HSPs might play an important role in such an educated regulatory mechanism and might provide a strategic target for developing therapies in various inflammatory disorders, including rheumatoid arthritis.